These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

271 related items for PubMed ID: 12697633

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Ertapenem once a day versus piperacillin-tazobactam every 6 hours for treatment of acute pelvic infections: a prospective, multicenter, randomized, double-blind study.
    Roy S, Higareda I, Angel-Muller E, Ismail M, Hague C, Adeyi B, Woods GL, Teppler H, Protocol 023 Study Group.
    Infect Dis Obstet Gynecol; 2003; 11(1):27-37. PubMed ID: 12839630
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Treatment of complicated urinary tract infection in adults: combined analysis of two randomized, double-blind, multicentre trials comparing ertapenem and ceftriaxone followed by appropriate oral therapy.
    Wells WG, Woods GL, Jiang Q, Gesser RM.
    J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii67-74. PubMed ID: 15150185
    [Abstract] [Full Text] [Related]

  • 5. Ertapenem versus piperacillin-tazobactam for treatment of mixed anaerobic complicated intra-abdominal, complicated skin and skin structure, and acute pelvic infections.
    Tellado J, Woods GL, Gesser R, McCarroll K, Teppler H.
    Surg Infect (Larchmt); 2002 Jun; 3(4):303-14. PubMed ID: 12697078
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Acquisition of resistant bowel flora during a double-blind randomized clinical trial of ertapenem versus piperacillin-tazobactam therapy for intraabdominal infections.
    DiNubile MJ, Chow JW, Satishchandran V, Polis A, Motyl MR, Abramson MA, Teppler H.
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3217-21. PubMed ID: 16048928
    [Abstract] [Full Text] [Related]

  • 9. A study evaluating the efficacy, safety, and tolerability of ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults.
    Ortiz-Ruiz G, Caballero-Lopez J, Friedland IR, Woods GL, Carides A, Protocol 018 Ertapenem Community-Acquired Pneumonia Study Group.
    Clin Infect Dis; 2002 Apr 15; 34(8):1076-83. PubMed ID: 11914996
    [Abstract] [Full Text] [Related]

  • 10. Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: results of a double-blind, randomized comparative phase III trial.
    Solomkin JS, Yellin AE, Rotstein OD, Christou NV, Dellinger EP, Tellado JM, Malafaia O, Fernandez A, Choe KA, Carides A, Satishchandran V, Teppler H, Protocol 017 Study Group.
    Ann Surg; 2003 Feb 15; 237(2):235-45. PubMed ID: 12560782
    [Abstract] [Full Text] [Related]

  • 11. General microbiology and in vitro susceptibility of anaerobes isolated from complicated skin and skin-structure infections in patients enrolled in a comparative trial of ertapenem versus piperacillin-tazobactam.
    Goldstein EJ, Citron DM, Merriam CV, Warren Y, Tyrrell KL, Gesser RM.
    Clin Infect Dis; 2002 Sep 01; 35(Suppl 1):S119-25. PubMed ID: 12173120
    [Abstract] [Full Text] [Related]

  • 12. In vitro activity of ertapenem: review of recent studies.
    Wexler HM.
    J Antimicrob Chemother; 2004 Jun 01; 53 Suppl 2():ii11-21. PubMed ID: 15150179
    [Abstract] [Full Text] [Related]

  • 13. Randomized, multicenter, double-blind study of efficacy, safety, and tolerability of intravenous ertapenem versus piperacillin/tazobactam in treatment of complicated intra-abdominal infections in hospitalized adults.
    Namias N, Solomkin JS, Jensen EH, Tomassini JE, Abramson MA.
    Surg Infect (Larchmt); 2007 Feb 01; 8(1):15-28. PubMed ID: 17381394
    [Abstract] [Full Text] [Related]

  • 14. Meta-analysis: ertapenem for complicated intra-abdominal infections.
    Falagas ME, Peppas G, Makris GC, Karageorgopoulos DE, Matthaiou DK.
    Aliment Pharmacol Ther; 2008 May 01; 27(10):919-31. PubMed ID: 18266994
    [Abstract] [Full Text] [Related]

  • 15. Impact of a Dynamic Microbiological Environment on the Clinical Efficacy of Ertapenem and Piperacillin/Tazobactam in the Treatment of Complicated Community-Acquired Intra-Abdominal Infection in Spain: A Cost-Consequence Analysis.
    Grau S, Lozano V, Valladares A, Cavanillas R, Xie Y, Nocea G.
    Appl Health Econ Health Policy; 2015 Aug 01; 13(4):369-79. PubMed ID: 25761545
    [Abstract] [Full Text] [Related]

  • 16. Safety and tolerability of ertapenem.
    Teppler H, Gesser RM, Friedland IR, Woods GL, Meibohm A, Herman G, Mistry G, Isaacs R.
    J Antimicrob Chemother; 2004 Jun 01; 53 Suppl 2():ii75-81. PubMed ID: 15150186
    [Abstract] [Full Text] [Related]

  • 17. Safety and tolerability of ertapenem versus ceftriaxone in a double-blind study performed in children with complicated urinary tract infection, community-acquired pneumonia or skin and soft-tissue infection.
    Arguedas A, Cespedes J, Botet FA, Blumer J, Yogev R, Gesser R, Wang J, West J, Snyder T, Wimmer W, Protocol 036 Study Group.
    Int J Antimicrob Agents; 2009 Feb 01; 33(2):163-7. PubMed ID: 18945594
    [Abstract] [Full Text] [Related]

  • 18. A randomized controlled clinical trial on piperacillin/tazobactam versus ticarcillin/clavulanic acid for the treatment of bacterial infections.
    Hou F, Li J, Gao L, Chen Y.
    Chin Med J (Engl); 1998 Nov 01; 111(11):1039-43. PubMed ID: 11189212
    [Abstract] [Full Text] [Related]

  • 19. Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia.
    Pertel PE, Bernardo P, Fogarty C, Matthews P, Northland R, Benvenuto M, Thorne GM, Luperchio SA, Arbeit RD, Alder J.
    Clin Infect Dis; 2008 Apr 15; 46(8):1142-51. PubMed ID: 18444848
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.